sch-29482 and Meningitis--Meningococcal

sch-29482 has been researched along with Meningitis--Meningococcal* in 1 studies

Trials

1 trial(s) available for sch-29482 and Meningitis--Meningococcal

Article	Year
Evaluation of Sch 29,482 in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrobial agents and chemotherapy, 1984, Volume: 25, Issue:4 Fifty-eight chronic carriers of Neisseria meningitidis were given 250 mg of Sch 29,482 or placebo orally every 6 h for 4 days. Although 22 of 29 subjects taking Sch 29,482 became culture negative while taking the drug, only five were culture negative 2 weeks posttherapy. There were no significant adverse reactions. Topics: Adult; Anti-Bacterial Agents; Carrier State; Double-Blind Method; Drug Evaluation; Humans; Lactams; Male; Meningitis, Meningococcal; Nasopharynx; Random Allocation	1984

Article

Year

Evaluation of Sch 29,482 in the eradication of Neisseria meningitidis from nasopharyngeal carriers.

Antimicrobial agents and chemotherapy, 1984, Volume: 25, Issue:4

Fifty-eight chronic carriers of Neisseria meningitidis were given 250 mg of Sch 29,482 or placebo orally every 6 h for 4 days. Although 22 of 29 subjects taking Sch 29,482 became culture negative while taking the drug, only five were culture negative 2 weeks posttherapy. There were no significant adverse reactions.

Topics: Adult; Anti-Bacterial Agents; Carrier State; Double-Blind Method; Drug Evaluation; Humans; Lactams; Male; Meningitis, Meningococcal; Nasopharynx; Random Allocation

1984